Drug intelligence / Profile preview

Tiaochang Xiaoyan

Development stage: Unknown
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Tiaochang Xiaoyan is a Traditional Chinese Medicine (TCM) formulation developed by The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (also known as the Guangdong Provincial Hospital of Chinese Medicine) for the treatment of inflammatory bowel diseases, specifically ulcerative colitis. Administered as a tablet, it is designed to regulate intestinal function and provide anti-inflammatory effects. Clinical research, including trial ChiCTR2400093130, evaluates the efficacy and safety of Tiaochang Xiaoyan when used in combination with standard therapies like mesalamine for patients with mild to moderate active ulcerative colitis, focusing on clinical remission and mucosal healing.

Other names: Tiaochang Xiaoyan tabletTiaochang Xiaoyan Pian

Beyond the preview

Go deeper on Tiaochang Xiaoyan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaochang Xiaoyan.

Explore the full profile